ROCK inhibitors for the treatment of ocular diseases

Ramin Nourinia, Shintaro Nakao, Souska Zandi, Sare Safi, Ali Hafezi-Moghadam, Hamid Ahmadieh

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The Rho-kinase/ROCK (Rho-associated coiled-coil-containing protein kinase) pathway is involved in the pathogenesis of multiple ocular and systemic disorders. Recently, ROCK inhibitors have been suggested as novel treatments for various ocular diseases. Several in vitro, in vivo and clinical studies have demonstrated the safety and efficacy of ROCK inhibitors in the management of ocular disorders such as corneal epithelial and endothelial damage, glaucoma, retinal and choroidal neovascularisation, diabetic macular oedema and optic nerve disorders. In this review, these studies are explored with focus on the relevant clinical investigations.

Original languageEnglish
JournalBritish Journal of Ophthalmology
Volume102
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'ROCK inhibitors for the treatment of ocular diseases'. Together they form a unique fingerprint.

  • Cite this

    Nourinia, R., Nakao, S., Zandi, S., Safi, S., Hafezi-Moghadam, A., & Ahmadieh, H. (2018). ROCK inhibitors for the treatment of ocular diseases. British Journal of Ophthalmology, 102(1). https://doi.org/10.1136/bjophthalmol-2017-310378